Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
48
VRAX Quote, Financials, Valuation and Earnings
Last price:
$0.39
Seasonality move
:
-34.96%
Day range:
$0.38 - $0.41
52-week range:
$0.35 - $3.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
591.52x
P/B ratio:
0.60x
Volume:
144.2K
Avg. volume:
10.3M
1-year change:
-79.38%
Market cap:
$2.6M
Revenue:
$6.3K
EPS (TTM):
-$1.25
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VRAX
Virax Biolabs Group Ltd.
|
$10K | -$0.18 | -- | -- | -- |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
$27.5M | -$0.21 | 84624.25% | -288.08% | $9.52 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | $7.99 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VRAX
Virax Biolabs Group Ltd.
|
$0.39 | -- | $2.6M | -- | $0.00 | 0% | 591.52x |
|
APM
Aptorum Group Ltd.
|
$1.13 | -- | $8.1M | 8.94x | $0.00 | 0% | 6.32x |
|
AUTL
Autolus Therapeutics Plc
|
$1.63 | $9.52 | $433.8M | -- | $0.00 | 0% | 8.46x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$3.64 | $17.94 | $2.3M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$3.56 | $104.00 | $14.8M | -- | $0.00 | 0% | -- |
|
TLSA
Tiziana Life Sciences Ltd.
|
$1.52 | $7.99 | $180.6M | -- | $0.00 | 0% | 2,803.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VRAX
Virax Biolabs Group Ltd.
|
-- | 0.664 | -- | 10.54x |
|
APM
Aptorum Group Ltd.
|
-- | -9.132 | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | 0.602 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VRAX
Virax Biolabs Group Ltd.
|
-- | -- | -100.4% | -100.4% | -- | -- |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | -- | -- |
Virax Biolabs Group Ltd. vs. Competitors
-
Which has Higher Returns VRAX or APM?
Aptorum Group Ltd. has a net margin of -- compared to Virax Biolabs Group Ltd.'s net margin of --. Virax Biolabs Group Ltd.'s return on equity of -100.4% beat Aptorum Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRAXVirax Biolabs Group Ltd.-- -- $8.4M APMAptorum Group Ltd.-- -- -- -
What do Analysts Say About VRAX or APM?
Virax Biolabs Group Ltd. has a consensus price target of --, signalling upside risk potential of 669.63%. On the other hand Aptorum Group Ltd. has an analysts' consensus of -- which suggests that it could grow by 13174.34%. Given that Aptorum Group Ltd. has higher upside potential than Virax Biolabs Group Ltd., analysts believe Aptorum Group Ltd. is more attractive than Virax Biolabs Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings VRAXVirax Biolabs Group Ltd.0 0 0 APMAptorum Group Ltd.0 0 0 -
Is VRAX or APM More Risky?
Virax Biolabs Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aptorum Group Ltd. has a beta of -0.206, suggesting its less volatile than the S&P 500 by 120.612%.
-
Which is a Better Dividend Stock VRAX or APM?
Virax Biolabs Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aptorum Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virax Biolabs Group Ltd. pays -- of its earnings as a dividend. Aptorum Group Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRAX or APM?
Virax Biolabs Group Ltd. quarterly revenues are --, which are smaller than Aptorum Group Ltd. quarterly revenues of --. Virax Biolabs Group Ltd.'s net income of -- is lower than Aptorum Group Ltd.'s net income of --. Notably, Virax Biolabs Group Ltd.'s price-to-earnings ratio is -- while Aptorum Group Ltd.'s PE ratio is 8.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virax Biolabs Group Ltd. is 591.52x versus 6.32x for Aptorum Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRAXVirax Biolabs Group Ltd.591.52x -- -- -- APMAptorum Group Ltd.6.32x 8.94x -- --
-
Which has Higher Returns VRAX or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to Virax Biolabs Group Ltd.'s net margin of -373.3%. Virax Biolabs Group Ltd.'s return on equity of -100.4% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital VRAXVirax Biolabs Group Ltd.-- -- $8.4M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About VRAX or AUTL?
Virax Biolabs Group Ltd. has a consensus price target of --, signalling upside risk potential of 669.63%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 484.19%. Given that Virax Biolabs Group Ltd. has higher upside potential than Autolus Therapeutics Plc, analysts believe Virax Biolabs Group Ltd. is more attractive than Autolus Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings VRAXVirax Biolabs Group Ltd.0 0 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is VRAX or AUTL More Risky?
Virax Biolabs Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock VRAX or AUTL?
Virax Biolabs Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virax Biolabs Group Ltd. pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRAX or AUTL?
Virax Biolabs Group Ltd. quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Virax Biolabs Group Ltd.'s net income of -- is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Virax Biolabs Group Ltd.'s price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virax Biolabs Group Ltd. is 591.52x versus 8.46x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRAXVirax Biolabs Group Ltd.591.52x -- -- -- AUTLAutolus Therapeutics Plc8.46x -- $21.1M -$78.6M
-
Which has Higher Returns VRAX or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Virax Biolabs Group Ltd.'s net margin of --. Virax Biolabs Group Ltd.'s return on equity of -100.4% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital VRAXVirax Biolabs Group Ltd.-- -- $8.4M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About VRAX or BDRX?
Virax Biolabs Group Ltd. has a consensus price target of --, signalling upside risk potential of 669.63%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 4786.03%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Virax Biolabs Group Ltd., analysts believe Biodexa Pharmaceuticals Plc is more attractive than Virax Biolabs Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings VRAXVirax Biolabs Group Ltd.0 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is VRAX or BDRX More Risky?
Virax Biolabs Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock VRAX or BDRX?
Virax Biolabs Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virax Biolabs Group Ltd. pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRAX or BDRX?
Virax Biolabs Group Ltd. quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Virax Biolabs Group Ltd.'s net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Virax Biolabs Group Ltd.'s price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virax Biolabs Group Ltd. is 591.52x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRAXVirax Biolabs Group Ltd.591.52x -- -- -- BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns VRAX or NCNA?
NuCana Plc has a net margin of -- compared to Virax Biolabs Group Ltd.'s net margin of --. Virax Biolabs Group Ltd.'s return on equity of -100.4% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital VRAXVirax Biolabs Group Ltd.-- -- $8.4M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About VRAX or NCNA?
Virax Biolabs Group Ltd. has a consensus price target of --, signalling upside risk potential of 669.63%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 584169.66%. Given that NuCana Plc has higher upside potential than Virax Biolabs Group Ltd., analysts believe NuCana Plc is more attractive than Virax Biolabs Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings VRAXVirax Biolabs Group Ltd.0 0 0 NCNANuCana Plc0 1 0 -
Is VRAX or NCNA More Risky?
Virax Biolabs Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock VRAX or NCNA?
Virax Biolabs Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virax Biolabs Group Ltd. pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRAX or NCNA?
Virax Biolabs Group Ltd. quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Virax Biolabs Group Ltd.'s net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Virax Biolabs Group Ltd.'s price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virax Biolabs Group Ltd. is 591.52x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRAXVirax Biolabs Group Ltd.591.52x -- -- -- NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns VRAX or TLSA?
Tiziana Life Sciences Ltd. has a net margin of -- compared to Virax Biolabs Group Ltd.'s net margin of --. Virax Biolabs Group Ltd.'s return on equity of -100.4% beat Tiziana Life Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRAXVirax Biolabs Group Ltd.-- -- $8.4M TLSATiziana Life Sciences Ltd.-- -- -- -
What do Analysts Say About VRAX or TLSA?
Virax Biolabs Group Ltd. has a consensus price target of --, signalling upside risk potential of 669.63%. On the other hand Tiziana Life Sciences Ltd. has an analysts' consensus of $7.99 which suggests that it could grow by 425.54%. Given that Virax Biolabs Group Ltd. has higher upside potential than Tiziana Life Sciences Ltd., analysts believe Virax Biolabs Group Ltd. is more attractive than Tiziana Life Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings VRAXVirax Biolabs Group Ltd.0 0 0 TLSATiziana Life Sciences Ltd.1 0 0 -
Is VRAX or TLSA More Risky?
Virax Biolabs Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tiziana Life Sciences Ltd. has a beta of -0.047, suggesting its less volatile than the S&P 500 by 104.653%.
-
Which is a Better Dividend Stock VRAX or TLSA?
Virax Biolabs Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tiziana Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virax Biolabs Group Ltd. pays -- of its earnings as a dividend. Tiziana Life Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRAX or TLSA?
Virax Biolabs Group Ltd. quarterly revenues are --, which are smaller than Tiziana Life Sciences Ltd. quarterly revenues of --. Virax Biolabs Group Ltd.'s net income of -- is lower than Tiziana Life Sciences Ltd.'s net income of --. Notably, Virax Biolabs Group Ltd.'s price-to-earnings ratio is -- while Tiziana Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virax Biolabs Group Ltd. is 591.52x versus 2,803.69x for Tiziana Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRAXVirax Biolabs Group Ltd.591.52x -- -- -- TLSATiziana Life Sciences Ltd.2,803.69x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
